leucovorin + fluorouracil + irinotecan + vemurafenib + cetuximab

This is a combination chemotherapy regimen consisting of leucovorin, fluorouracil, irinotecan, vemurafenib, and cetuximab. The combination targets multiple pathways in cancer cells: - Leucovorin enhances the cytotoxic effects of fluorouracil by stabilizing the binding of fluorouracil metabolite (FdUMP) to thymidylate synthase - Fluorouracil is an antimetabolite that disrupts DNA synthesis - Irinotecan is a topoisomerase I inhibitor that prevents DNA unwinding and replication - Vemurafenib is a BRAF inhibitor targeting the BRAF V600E mutation - Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) This combination is likely used for metastatic colorectal cancer with BRAF V600E mutations, combining traditional chemotherapy with targeted therapy approaches.